Component

Collagen

Species, preparation, dose and limitations are retained on linked claims.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

Where it participates (unsigned role)

  1. At 2 micromolar, eugenol inhibited collagen- and arachidonic-acid-induced aggregation in human platelets but did not inhibit thrombin- or U46619-induced aggregation.

    Eugenol → Collagen- and arachidonic-acid-induced human platelet aggregation source_derived_draftungraded
    Experimental context and source evidence
    dose
    Eugenol 2 micromolar
    duration
    Acute
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Washed human platelets; ADP-treated mouse pulmonary-thrombosis arm
    limitations
    Ex-vivo platelet inhibition and mouse thrombosis do not establish oral antithrombotic efficacy or bleeding safety in humans.
    nutrient_topic
    Eugenol chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Eugenol
    organism
    Washed human platelets; ADP-treated mouse pulmonary-thrombosis arm
    plain_language
    At 2 micromolar, eugenol inhibited collagen- and arachidonic-acid-induced aggregation in human platelets but did not inhibit thrombin- or U46619-induced aggregation.
    primary_references
    Eugenol Suppresses Platelet Activation and Mitigates Pulmonary Thromboembolism in Humans and Murine Models. (2024). https://pubmed.ncbi.nlm.nih.gov/38396774/ DOI: 10.3390/ijms25042098
    route
    In vitro; mouse intervention
    tissue
    Agonist-specific platelet aggregation

    Eugenol: mechanism of action and interactions (2026-09-20) · lines 11–20

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Washed human platelets; ADP-treated mouse pulmonary-thrombosis arm · source_derived_draft · unverified_draft

    ## eugenol-platelet-agonist-selectivity At 2 micromolar, eugenol inhibited collagen- and arachidonic-acid-induced aggregation in human platelets but did not inhibit thrombin- or U46619-induced aggregation. Model/species: Washed human platelets; ADP-treated mouse pulmonary-thrombosis arm Tissue/system: Agonist-specific platelet aggregation Exposure: Eugenol 2 micromolar Route: In vitro; mouse intervention Duration: Acute Limits: Ex-vivo platelet inhibition and mouse thrombosis do not establish oral antithrombotic efficacy or bleeding safety in humans. Primary reference: Eugenol Suppresses Platelet Activation and Mitigates Pulmonary Thromboembolism in Humans and Murine Models. (2024). https://pubmed.ncbi.nlm.nih.gov/38396774/ DOI: 10.3390/ijms25042098 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

  2. Capsaicin, N-oleoyldopamine and N-arachidonoyl-dopamine inhibited ADP-induced platelet aggregation in a concentration-dependent manner, while arachidonic-acid-induced aggregation was inhibited by capsaicin, dihydrocapsaicin and N-arachidonoyl-dopamine but not by N-oleoyldopamine, and collagen-induced aggregation was inhibited only by the endogenous vanilloids and not by capsaicin or dihydrocapsaicin.

    Dihydrocapsaicin → Capsaicin source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/dihydrocapsaicin-research/24953906.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "8d11f6733abf59c36bf8e2b6ed6f44f759cab3fdd209ff3c84c21b20e178a717", "start_char": 0, "end_char": 1870, "text_sha256": "8d11f6733abf59c36bf8e2b6ed6f44f759cab3fdd209ff3c84c21b20e178a717"}
    experimental_model
    In-vitro human platelet aggregation with agonist-specified stimulation and an LDH viability control
    exposure
    Capsaicin and dihydrocapsaicin against the endogenous vanilloids N-oleoyldopamine and N-arachidonoyl-dopamine, with ADP, collagen and arachidonic acid as agonists
    limitations
    The agonist-by-agonist design is what makes this useful: it separates the two plant compounds where a single-agonist study would have merged them. A TRPV1 antagonist control was included.
    nutrient_topic
    Dihydrocapsaicin research collection; topical membership is not evidence of a direct clinical effect, and dihydrocapsaicin is recorded separately from capsaicin. · Dihydrocapsaicin
    organism
    Human
    plain_language
    Capsaicin blocks clumping triggered two ways; dihydrocapsaicin blocks only one of them.
    primary_references
    [dhc-p24953906] Vanilloid-like agents inhibit aggregation of human platelets. (2014). https://pubmed.ncbi.nlm.nih.gov/24953906/ DOI: 10.1016/j.thromres.2014.05.038
    tissue_or_cell_type
    Platelets

    Dihydrocapsaicin: the second capsaicinoid, the hypothermia it is used to induce, what the gut and liver do to it, and what it does without TRPV1 (2026-09-21) · lines 153–164

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · In-vitro human platelet aggregation with agonist-specified stimulation and an LDH viability control · source_derived_draft · unverified_draft

    ### dhc-platelet-divergence Capsaicin, N-oleoyldopamine and N-arachidonoyl-dopamine inhibited ADP-induced platelet aggregation in a concentration-dependent manner, while arachidonic-acid-induced aggregation was inhibited by capsaicin, dihydrocapsaicin and N-arachidonoyl-dopamine but not by N-oleoyldopamine, and collagen-induced aggregation was inhibited only by the endogenous vanilloids and not by capsaicin or dihydrocapsaicin. Condition category: normal nutrient_topic: Dihydrocapsaicin research collection; topical membership is not evidence of a direct clinical effect, and dihydrocapsaicin is recorded separately from capsaicin. plain_language: Capsaicin blocks clumping triggered two ways; dihydrocapsaicin blocks only one of them. organism: Human tissue_or_cell_type: Platelets experimental_model: In-vitro human platelet aggregation with agonist-specified stimulation and an LDH viability control limitations: The agonist-by-agonist design is what makes this useful: it separates the two plant compounds where a single-agonist study would have merged them. A TRPV1 antagonist control was included. exposure: Capsaicin and dihydrocapsaicin against the endogenous vanilloids N-oleoyldopamine and N-arachidonoyl-dopamine, with ADP, collagen and arachidonic acid as agonists evidence_span: {"source_cache": "artifacts/dihydrocapsaicin-research/24953906.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "8d11f6733abf59c36bf8e2b6ed6f44f759cab3fdd209ff3c84c21b20e178a717", "start_char": 0, "end_char": 1870, "text_sha256": "8d11f6733abf59c36bf8e2b6ed6f44f759cab3fdd209ff3c84c21b20e178a717"} [dhc-p24953906] Vanilloid-like agents inhibit aggregation of human platelets. (2014). https://pubmed.ncbi.nlm.nih.gov/24953906/ DOI: 10.1016/j.thromres.2014.05.038
    Complete structured claim and evidence

  3. Hericenone B inhibited collagen-induced aggregation in washed rabbit and human platelets but did not inhibit aggregation induced by U46619, ADP, thrombin, adrenaline, arachidonic acid or convulxin.

    Hericenone B → Collagen-induced human platelet aggregation source_derived_draftungraded
    Experimental context and source evidence
    dose
    Purified hericenone B with multiple agonists
    duration
    Acute
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Washed rabbit and human platelets
    limitations
    The proposed integrin-alpha2/beta1-to-arachidonate step was not a human oral antithrombotic trial.
    nutrient_topic
    Hericenones & Erinacines chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Hericenones and erinacines
    organism
    Washed rabbit and human platelets
    plain_language
    Hericenone B inhibited collagen-induced aggregation in washed rabbit and human platelets but did not inhibit aggregation induced by U46619, ADP, thrombin, adrenaline, arachidonic acid or convulxin.
    primary_references
    Inhibitory effect of hericenone B from Hericium erinaceus on collagen-induced platelet aggregation. (2010). https://pubmed.ncbi.nlm.nih.gov/20637576/ DOI: 10.1016/j.phymed.2010.05.004
    route
    In vitro
    tissue
    Agonist-specific platelet aggregation

    Hericenones & Erinacines: mechanism of action and interactions (2026-09-20) · lines 55–64

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Washed rabbit and human platelets · source_derived_draft · unverified_draft

    ## hericenones-erinacines-hericenone-b-platelets Hericenone B inhibited collagen-induced aggregation in washed rabbit and human platelets but did not inhibit aggregation induced by U46619, ADP, thrombin, adrenaline, arachidonic acid or convulxin. Model/species: Washed rabbit and human platelets Tissue/system: Agonist-specific platelet aggregation Exposure: Purified hericenone B with multiple agonists Route: In vitro Duration: Acute Limits: The proposed integrin-alpha2/beta1-to-arachidonate step was not a human oral antithrombotic trial. Primary reference: Inhibitory effect of hericenone B from Hericium erinaceus on collagen-induced platelet aggregation. (2010). https://pubmed.ncbi.nlm.nih.gov/20637576/ DOI: 10.1016/j.phymed.2010.05.004 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards